EICHORCondition: Prostate Cancer · Sponsor: Jiangsu HengRui Medicine Co., Ltd.
The purpose of this study is to evaluate the efficacy, and safety of HRS-5041 tablets combined with antitumor therapy in subjects with advanced prostate cancer.
This description comes directly from the study's public registry record.
Jianpo Lian · +0518-81220121 · jianpo.lian.jl3@hengrui.com
Always discuss trial participation with your own doctor first.
| The Second Affiliated Hospital of Harbin Medical University | Harbin, Heilongjiang, China | Recruiting |
| Shanghai Jiao Tong University School of Medicine, Renji Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
Sponsor or site team? See the site landscape for this trial — listed sites, countries, and recruiting-density context.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06568094